Seres Free Cash Flow vs Begin Period Cash Flow Analysis

MCRB Stock  USD 0.88  0.02  2.33%   
Seres Therapeutics financial indicator trend analysis is much more than just breaking down Seres Therapeutics prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Seres Therapeutics is a good investment. Please check the relationship between Seres Therapeutics Free Cash Flow and its Begin Period Cash Flow accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Seres Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.
For information on how to trade Seres Stock refer to our How to Trade Seres Stock guide.

Free Cash Flow vs Begin Period Cash Flow

Free Cash Flow vs Begin Period Cash Flow Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Seres Therapeutics Free Cash Flow account and Begin Period Cash Flow. At this time, the significance of the direction appears to have pay attention.
The correlation between Seres Therapeutics' Free Cash Flow and Begin Period Cash Flow is -0.74. Overlapping area represents the amount of variation of Free Cash Flow that can explain the historical movement of Begin Period Cash Flow in the same time period over historical financial statements of Seres Therapeutics, assuming nothing else is changed. The correlation between historical values of Seres Therapeutics' Free Cash Flow and Begin Period Cash Flow is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Free Cash Flow of Seres Therapeutics are associated (or correlated) with its Begin Period Cash Flow. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Begin Period Cash Flow has no effect on the direction of Free Cash Flow i.e., Seres Therapeutics' Free Cash Flow and Begin Period Cash Flow go up and down completely randomly.

Correlation Coefficient

-0.74
Relationship DirectionNegative 
Relationship StrengthWeak

Free Cash Flow

The amount of cash a company generates after accounting for cash outflows to support operations and maintain its capital assets.

Begin Period Cash Flow

The amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities.
Most indicators from Seres Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Seres Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Seres Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.
For information on how to trade Seres Stock refer to our How to Trade Seres Stock guide.The current year's Selling General Administrative is expected to grow to about 92.1 M, whereas Issuance Of Capital Stock is forecasted to decline to about 12.3 M.
 2023 2024 (projected)
Non Recurring1.3M1.2M
Reconciled Depreciation6.2M5.5M

Seres Therapeutics fundamental ratios Correlations

0.670.790.420.65-0.06-0.770.740.850.710.470.660.90.750.490.730.940.820.590.70.490.540.80.680.760.59
0.670.88-0.180.950.49-0.90.640.680.910.740.510.40.910.360.870.460.90.930.450.060.840.90.850.870.9
0.790.88-0.110.90.35-0.980.670.760.90.790.550.580.970.60.950.640.970.880.740.440.880.970.920.960.88
0.42-0.18-0.11-0.27-0.520.150.240.17-0.16-0.30.290.66-0.140.01-0.270.61-0.03-0.30.00.26-0.36-0.05-0.33-0.06-0.31
0.650.950.9-0.270.62-0.910.560.580.970.840.430.350.920.320.930.420.910.970.570.140.910.910.920.840.98
-0.060.490.35-0.520.62-0.4-0.18-0.240.60.670.09-0.380.45-0.110.41-0.310.40.670.03-0.260.650.430.440.340.69
-0.77-0.9-0.980.15-0.91-0.4-0.62-0.74-0.92-0.78-0.63-0.53-0.98-0.58-0.95-0.6-0.98-0.9-0.72-0.44-0.9-0.98-0.92-0.98-0.89
0.740.640.670.240.56-0.18-0.620.750.50.190.240.710.560.540.580.710.620.410.640.360.310.60.520.60.43
0.850.680.760.170.58-0.24-0.740.750.590.420.550.790.720.550.740.820.740.550.570.410.530.720.70.740.51
0.710.910.9-0.160.970.6-0.920.50.590.860.570.430.940.310.930.50.930.960.590.20.920.940.920.870.97
0.470.740.79-0.30.840.67-0.780.190.420.860.380.230.850.190.820.310.780.920.340.070.940.810.820.740.92
0.660.510.550.290.430.09-0.630.240.550.570.380.570.660.280.520.610.670.490.380.40.510.660.490.710.43
0.90.40.580.660.35-0.38-0.530.710.790.430.230.570.520.490.490.990.60.290.570.60.250.580.430.560.29
0.750.910.97-0.140.920.45-0.980.560.720.940.850.660.520.510.950.590.980.940.610.320.920.980.920.960.91
0.490.360.60.010.32-0.11-0.580.540.550.310.190.280.490.510.490.50.580.310.610.730.330.560.430.60.27
0.730.870.95-0.270.930.41-0.950.580.740.930.820.520.490.950.490.550.930.910.70.350.910.930.990.890.92
0.940.460.640.610.42-0.31-0.60.710.820.50.310.610.990.590.50.550.670.370.610.590.340.650.490.620.37
0.820.90.97-0.030.910.4-0.980.620.740.930.780.670.60.980.580.930.670.910.670.450.891.00.890.970.89
0.590.930.88-0.30.970.67-0.90.410.550.960.920.490.290.940.310.910.370.910.440.110.970.920.910.860.99
0.70.450.740.00.570.03-0.720.640.570.590.340.380.570.610.610.70.610.670.440.710.490.660.650.670.51
0.490.060.440.260.14-0.26-0.440.360.410.20.070.40.60.320.730.350.590.450.110.710.220.430.290.460.12
0.540.840.88-0.360.910.65-0.90.310.530.920.940.510.250.920.330.910.340.890.970.490.220.910.910.870.96
0.80.90.97-0.050.910.43-0.980.60.720.940.810.660.580.980.560.930.651.00.920.660.430.910.90.970.9
0.680.850.92-0.330.920.44-0.920.520.70.920.820.490.430.920.430.990.490.890.910.650.290.910.90.840.92
0.760.870.96-0.060.840.34-0.980.60.740.870.740.710.560.960.60.890.620.970.860.670.460.870.970.840.82
0.590.90.88-0.310.980.69-0.890.430.510.970.920.430.290.910.270.920.370.890.990.510.120.960.90.920.82
Click cells to compare fundamentals

Seres Therapeutics Account Relationship Matchups

Seres Therapeutics fundamental ratios Accounts

201920202021202220232024 (projected)
Total Assets132.4M342.9M354.9M348.8M358.6M225.8M
Other Current Liab10.9M21.7M38.5M105.0M73.9M77.6M
Total Current Liabilities46.0M46.4M82.3M85.6M98.7M103.6M
Total Stockholder Equity(48.3M)174.8M131.5M10.8M(44.9M)(42.6M)
Property Plant And Equipment Net30.9M22.9M36.1M134.0M132.3M138.9M
Net Debt(20.3M)(75.3M)(130.8M)(440K)86.0M90.3M
Retained Earnings(459.6M)(548.8M)(614.4M)(864.5M)(978.2M)(929.3M)
Accounts Payable4.9M4.0M13.7M17.4M3.6M6.7M
Cash65.1M116.0M180.0M163.0M128.0M93.9M
Non Current Assets Total32.3M74.2M51.2M154.0M183.2M192.3M
Cash And Short Term Investments94.8M253.6M290.7M181.3M128.0M156.3M
Common Stock Shares Outstanding56.6M79.8M91.7M108.1M128.0M134.4M
Other Current Assets33.3M11.5M25.8M13.4M9.1M10.4M
Total Liab180.8M168.2M223.4M338.0M403.5M423.6M
Total Current Assets100.2M268.8M303.6M194.8M175.4M166.7M
Common Stock70K91K92K125K135K141.8K
Short Long Term Debt Total44.8M40.8M49.2M162.6M213.9M224.6M
Other Liab94.4M86.6M98.5M93.9M108.0M78.0M
Current Deferred Revenue25.8M22.6M16.8M4.3M7.7M13.6M
Common Stock Total Equity70K91K92K125K143.8K150.9K
Liabilities And Stockholders Equity132.4M342.9M354.9M348.8M358.6M245.7M
Non Current Liabilities Total134.8M121.8M141.1M252.4M304.8M320.0M
Other Stockholder Equity411.3M723.5M745.8M875.2M933.2M979.9M
Property Plant And Equipment Gross30.9M22.9M36.1M134.0M183.4M192.6M
Accumulated Other Comprehensive Income(27.7M)(47K)(60K)(12K)(13.8K)(14.5K)
Short Term Debt4.5M5.6M13.2M4.1M13.4M7.8M
Property Plant Equipment19.5M13.9M36.1M23.0M26.4M21.7M
Net Tangible Assets(48.3M)174.8M131.5M10.8M9.7M9.2M
Short Term Investments113.9M0.029.7M137.6M110.7M18.3M
Retained Earnings Total Equity(459.6M)(548.8M)(614.4M)(864.5M)(778.1M)(739.2M)
Capital Surpluse411.3M723.5M745.8M875.2M1.0B552.2M
Non Current Liabilities Other110.1M97.1M116.5M201.8M1.6M1.5M
Capital Lease Obligations20.1M15.7M24.6M111.5M112.4M118.0M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Seres Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Seres Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Seres Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Seres Therapeutics Stock:
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Seres Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.
For information on how to trade Seres Stock refer to our How to Trade Seres Stock guide.
You can also try the Portfolio Suggestion module to get suggestions outside of your existing asset allocation including your own model portfolios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Seres Therapeutics. If investors know Seres will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Seres Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.40)
Revenue Per Share
0.871
Quarterly Revenue Growth
(0.93)
Return On Assets
(0.1)
Return On Equity
(15.56)
The market value of Seres Therapeutics is measured differently than its book value, which is the value of Seres that is recorded on the company's balance sheet. Investors also form their own opinion of Seres Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Seres Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Seres Therapeutics' market value can be influenced by many factors that don't directly affect Seres Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Seres Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Seres Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Seres Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.